Somagenetix is a spin-off from the University of Zurich leveraging scientific, clinical & commercial expertise to solve unmet medical needs.
With our gene therapy platform, we aim at becoming a leading company with first & best-in-class treatments for phagocyte-related disorders.
Products, services, technology
We focus on high unmet medical need, devastating diseases with high morbidity, mortality & limited treatment options.
Phagocure our gene therapy platform allows targeted & safe CURE a wide range of immunodeficiencies (lead program), neurological, neuro-metabolic & phagocytes related diseases.
Cooperation possibilities
- Series A financing round successfully completed- interested in meeting investors
- Open to strategic partnering - interested in meeting Pharma & Biotech to leverage internal R&D capabilities and deliver synergies for both companies.
- http://www.somagenetix.com
- +41 78 849 58 97
- Send an email
- Jonathan Chriqui
Some insights
The objective of Somagenetix is to provide a once in a lifetime treatment aiming at curing children and adults suffering from highly debilitating inherited genetic diseases that currently have limited options or no treatment available.
My team is composed of seasoned academic professional experts in Cell and Gene therapy with a high level of knowledge and more importantly of experience in this field. We now need to integrate few people with industry background to complete & strengthen the team and professionalise our approach.
For our small start-up Company being part of the Swiss ecosystem is very important to get access to the network, get introduced to Investors. It is also very valuable to share and benefit from other companies experience.